Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Codexis, a developer of proprietary custom biocatalysts, has signed a licensing agreement with Teva Pharmaceutical Industries to produce an important publicly-undisclosed generic product, using a proprietary Codexis biocatalyst.
Subscribe to our email newsletter
Under the agreement, Teva would be using the Codexis process for key process steps in the manufacture of this product, assuming technical milestones are met. Financial terms were not disclosed.
Alan Shaw, president and CEO of Codexis, said: “Codexis is very pleased to be partnering with Teva, providing high value technology in the extremely cost-competitive generics marketplace.
“Our proven technology reduces the cost of pharmaceutical process development and manufacturing, and provides our partners with a significant competitive advantage as they respond to increasing market demands for lower cost pharmaceuticals.”